Boston-based Rapport Therapeutics has raised a $100M Series A to develop therapies for neurological disorders.
Johnson & Johnson participated in the funding round.
- In
neurology, many currently available medicines work by blocking or
boosting so-called receptor proteins. But these proteins often are found
throughout the brain and central nervous system and even other parts of
the body, which can limit a medicine’s effect or cause safety issues.
- Rapport
Therapeutics offers a solution that helps identify precision-targeted
small-molecule drugs that can potentially transform the treatment of
neurological disorders.
- The Series A round was led by Third Rock Ventures, ARCH Venture Partners, and Johnson & Johnson Innovation.
- The company aims to use the funds to accelerate growth and expand to new markets.
